Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients

Journal of Nutrition

Volumn 141, Issue 7, 2011, Pages 1233-1238

  Samocha Bonet, Dorit ^a   Wong, Olivia ^a   Synnott, Emma Leigh ^a   Piyaratna, Naomi ^a   Douglas, Ashley ^a   Gribble, Fiona M ^b   Holst, Jens J ^c   Chisholm, Donald J ^a,d   Greenfield, Jerry R ^a,d,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; SITAGLIPTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESPONSE; LIFESTYLE MODIFICATION; LOW FAT DIET; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SATIETY;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUTAMINE; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 79960330206     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.139824     Document Type: Article

References (34)

1. Bonadonna RC, Stumvoll M, Fritsche A, Muggeo M, Haring H, Bonora E, van Haeften TW. Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function. Diabetes. 2003;52:470-80.
2. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vanttinen M, Stancakova A, Jansson PA, Pellme F, Holst JJ, et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51:502-11.
3. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3: 153-65.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87:1409-39.
5. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsboll T. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol. 2006;155:485-93.
6. Vollmer K, Holst JJ, Baher B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678-87.
7. Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, Holst JJ, Meier JJ. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009;94:1379-85.
8. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-23.
9. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-13.
10. Salehi M, Prigeon RL, Aulinger B, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010;59:1330-7.
11. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.
12. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53 Suppl 3:S190-6.
13. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
14. Wynne K, Bloom SR. The role of oxyntomodulin and peptide tyrosinetyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab. 2006;2:612-20.
15. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr. 2006; 26:391-411.
16. Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab. 2010;21:59-68.
17. Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr. 2009;89:106-13.
18. Galera SC, Fechine F, Teixeira MJ, Branco Coelho ZC, de Vasconcelos RC, de Vasconcelos PR. The safety of oral use of l-glutamine in middleaged and elderly individuals. Nutrition. 2010;26:375-81.
19. Menge BA, Schrader H, Ritter PR, Ellrichmann M, UhlW, Schmidt WE, Meier JJ. Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul Pept. 2010;160:75-80.
20. Ward E, Picton S, Reid U, Thomas D, Gardener C, Smith M, Henderson M, Holden V, Kinsey S, et al. Oral glutamine in paediatric oncology patients: a dose finding study. Eur J Clin Nutr. 2003;57:31-6.
21. Gandini C, Delorenzi D, Kitsos M, Massolini G, Caccialanza G. HPLC determination of pyroglutamic acid as a degradation product in parenteral amino-acid formulations. Chromatographia. 1993;36:75-8.
22. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535-9.
23. Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf). 2009;71:500-6.
24. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc. 1961; 56:52-64.
25. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56:117-26.
26. Reimann F, Williams L, da Silva Xavier G, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia. 2004;47:1592-601.
27. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med. 2010;12:e1.
28. Lobo DN, Hendry PO, Rodrigues G, Marciani L, Totman JJ, Wright JW, Preston T, Gowland P, Spiller RC, et al. Gastric emptying of three liquid oral preoperative metabolic preconditioning regimens measured by magnetic resonance imaging in healthy adult volunteers: a randomised double-blind, crossover study. lin Nutr. 2009;28:636-41.
29. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, et al. Endogenous glucagonlike peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215-21.
30. Barrett EJ, Gusberg R, Ferrannini E, Tepler J, Felig P, Jacob R, Smith D, DeFronzo RA. Amino acid and glucose metabolism in the postabsorptive state and following amino acid ingestion in the dog. Metabolism. 1986;35:709-17.
31. Henry RR. Protein content of the diabetic diet. Diabetes Care. 1994; 17:1502-13.
32. Herman GA, Bergman A, Stevens C, Kotey P, Yi BM, Zhao P, Dietrich B, Golor G, Schrodter A, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 006;91:4612-9.
33. Hansen L, Hartmann B, Mineo H, Holst JJ. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept. 2004;118:11-8.
34. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 SUPPL 1:S11-61.